Back to search

Article

Long-term outcome of Tyrosine Kinase Inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase: A single-center experience in China

2022-03-30

Abstract excerpt

Backgroud: Tyrosine kinase inhibitors (TKIs) has gradually replaced HSCT as the first-line treatment for pediatric patients with chronic-phase Chronic myeloid leukemia (CML-CP). However, there are few reports detailing the long-term effect and safety of TKIs in Chinese children with CML-CP. Procedure: A total of 58 patients (43 children and 15 adolescents) with newly diagnosed CML-CP received imatinib mesylate (IM...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
773374bf-51e8-5928-a241-e39f556e5e3c
DOI
10.22541/au.164864205.56736755/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Long-term outcome of Tyrosine Kinase Inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase: A single-center experience in ChinaDOI 10.22541/au.164864205.56736755/v1
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Semantic proximity
Best First Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia in Adults: A Network Meta-AnalysisSemantic proximity
The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective studySemantic proximity
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.Semantic proximity
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on behalf of the Polish Adult Leukaemia GroupSemantic proximity
Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity
Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaSemantic proximity
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.Semantic proximity
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity
[Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review].Semantic proximity
Olverembatinib (HQP1351), a highly safe and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialSemantic proximity
Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.